Julie M. Reed, the new executive director of the Biosimilars Forum, shares how the Forum is preparing for the US market introduction of the first FDA-approved adalimumab biosimilars.
Julie M. Reed, the new executive director of the Biosimilars Forum, shares how the Forum is preparing for the US market introduction of the first FDA-approved adalimumab biosimilars.
Transcript:
How will you and the Forum be preparing for the launches of the first FDA adalimumab biosimilars coming early next year?
I think most of the ones that are approved [were developed by] our members. And like interchangeability, we're going to do a lot of education on that. And I think that'll be one of our biggest preparations: the education, and monitoring, and watching for any misinformation. So, we're excited. Our members are excited. It's an industry, so we're excited to see how quickly we'll achieve those cost savings that you guys are predicting because we'd like to surpass your predictions and we think it could happen.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs
August 3rd 2025Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.
Escaping the Void: All Things Biosimilars With Craig & G
August 3rd 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."